Abrocitinib
Cibinqo Abrocitinib is being developed by Pfizer for the treatment of atopic dermatitis (eczema). It is an experimental once-daily oral Janus kinase 1 (JAK1) inhibitor. The JAK/STAT pathway is an important factor in inflammation and pruritus in atopic dermatitis. Multiple receptors and signaling cascades are involved in eczema-related inflammation and itch, one of which is … Read more